Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi-315: Subcutaneous versus intravenous tarlatamab in recurrent extensive-stage small cell lung cancer
ChiCTR2600131273Phase 3Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Sep 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tarlatamab in small cell lung cancer (SCLC) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoints: AUC C2D1-D15, Ctrough at C2D15 and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2600131273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131273.